India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Home
/
update
/
details

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

NextEdge Admin

09 Jan 2025

2 min 22 sec

Colorectal Cancer Screening,diagnostics,FDA,Bio-Rad,Droplet Digital™ PCR

Geneoscopy, Inc., a life sciences company focused on gastrointestinal diagnostics, has raised $105 million in a Series C funding round led by Bio-Rad Laboratories (NYSE: BIO and BIO.B), with participation from Labcorp (NYSE: LH), Petrichor, Morningside Ventures, and others. This funding supports the commercialization of ColoSense, Geneoscopy’s FDA-approved, at-home stool-based colorectal cancer screening test, and furthers the development of innovative diagnostics for inflammatory bowel disease.

Geneoscopy’s proprietary stool-derived RNA platform, combined with Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology, enables highly sensitive colorectal cancer detection. Through collaboration with Labcorp, ColoSense will be widely accessible to healthcare providers, enhancing screening options for patients.

“Securing this financing underscores investor confidence in our RNA technology to address critical gaps in colorectal cancer and inflammatory bowel disease diagnostics,” said Andrew Barnell, CEO and co-founder of Geneoscopy. “With this support, we will continue delivering innovative solutions that improve patient outcomes.”

Bio-Rad CEO Norman Schwartz added, “Geneoscopy’s ColoSense test demonstrates remarkable sensitivity and aligns with our mission to improve healthcare outcomes through digital biology innovations.”

Colorectal cancer remains the second deadliest cancer in the U.S., with increasing incidence in individuals under 50. Despite revised screening guidelines lowering the recommended age to 45, many eligible individuals remain unscreened. Geneoscopy aims to bridge this gap with ColoSense, providing a non-invasive, highly accurate screening alternative.

Andrew Barnell will present Geneoscopy’s vision and funding plans at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025.